Dr. Alan Shackelford gained national attention for his breakthrough treatment of a young patient with Dravet Syndrome. Based upon Dr. Shackelford's real-world experience, Shackelford Pharma, Inc. was formed to develop medicines for neurological diseases with significant unmet patient needs.
A world-class experienced team of entrepreneurs, scientists and pharmaceutical commercial personnel are backing Dr. Shackelford’s real-world clinical experience.
The company's lead drug candidate, SP1707, is supported by more than 133 patient treatment years of data in patients under Dr. Shackelford's care as well as data from preclinical animal studies. The company has filed its foundational patents related to the use of SP1707 for the treatment of seizure disorders, either alone or as adjunctive therapy. This application included both supportive preclinical and clinical data.